Pharmaceutical

FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials

FibroGen’s pamrevlumab failed to prove its efficacy in two Phase III trials prompting the company to initiate cost-saving measures.

Aug 1, 2024 - 04:00
FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials
FibroGen’s pamrevlumab failed to prove its efficacy in two Phase III trials prompting the company to initiate cost-saving measures.
Read the original article

Tags:

Previous Article

Magazine: Left in limbo: when pharma halts rare disease research

Next Article

Imunon’s shares soar after IL-12 therapy success in Phase II trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sanders issues warning to Novo Nordisk amid GLP-1 drug price investigation

Sanders issues warning to Novo Nordisk amid GLP-1 drug ...

May 19, 2024

Q&A: A biotech VC leader shares her next big bets

Q&A: A biotech VC leader shares her next big bets

Feb 29, 2024

Half of people worldwide at risk of developing mental health condition by age 75, per new study

Half of people worldwide at risk of developing mental h...

Aug 9, 2023